Mitoxantrone in epithelial carcinoma of the ovary. A Southwest Oncology Group study

R. D. Hilgers, D. D. Von Hoff, S. E. Rivkin, D. S. Alberts

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Thirty-nine patients with advanced heavily pretreated epithelial carcinoma of the ovary were treated with mitoxantrone (dihydroxyanthracenedione hydrochloride). Twenty-five patients were started at a dose of 12 mg/m2 q 21d and 13 patients, with compromised bone marrow, at a dose of 10 mg/m2 q 21d. Two stable responses (6%) occurred in 31 fully evaluable patients. The median duration of survival was 17 weeks. The principal toxicity, hematopoietic (primarily leukopenia), was mild and well tolerated. We conclude that mitoxantrone is a relatively inactive drug in the treatment of epithelial ovarian carcinoma.

Original languageEnglish (US)
Pages (from-to)499-501
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume7
Issue number5
DOIs
StatePublished - 1984
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Mitoxantrone in epithelial carcinoma of the ovary. A Southwest Oncology Group study'. Together they form a unique fingerprint.

Cite this